CA
GMAB icon

CoreCap Advisors’s Genmab GMAB Stock Holding History

CoreCap Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110 Buy
+4
New +$106 ﹤0.01% 3067

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CoreCap Advisors's GMAB Position: Q2 2026 in Review

CoreCap Advisors opened a new position in Genmab (GMAB) in Q2 2026: 4 shares worth $110. The stake represents ﹤0.01% of the portfolio and ranks #3067 among its holdings.

289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • CoreCap Advisors held 4 shares of Genmab worth $110 as of Q2 2026.
  • Genmab was a new CoreCap Advisors position in Q2 2026.
  • Genmab made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3067 holding.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.